SEARCH

SEARCH BY CITATION

References

  • Alessi, M. C. & Juhan-Vague, I. (2006) PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 26, 22002207.
  • Anand, S., Yi, Q., Gerstein, H., Lonn, E., Jacobs, R., Vuksan, V., Teo, K., Davis, B., Montague, P. & Yusuf, S. (2003) Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108, 420425.
  • Bollen, K. A. (1989) Structural equations with latent variables. New York : Wiley Interscience.
  • Botto, L. D. & Khoury, M. J. (2001) Commentary: Facing the challenge of gene–environment interaction: The two-by-four table and beyond. Am J Epidemiol 153, 10161020.
  • Cambien, F., Warnet, J. M., Eschwege, E., Jacqueson, A., Richard, J. L. & Rosselin, G. (1987) Body mass, blood pressure, glucose, and lipids. Arterioscler Thromb Vasc Biol 7, 197202.
  • Dallongeville, J., Lussier-Cacan, S. & Davignon, J. (1992) Modulation of plasma triglyceride levels by apoE phenotype: A meta-analysis. J Lipid Res 33, 447454.
  • Davignon, J., Gregg, R. E. & Sing, C. F. (1988) Apolipoprotein E polymorphism and atherosclerosis. Arterioscler Thromb Vasc Biol 8, 121.
  • Davignon, J., Cohn, J. S., Mabile, L. & Bernier, L. (1999) Apolipoprotein E and atherosclerosis: Insight from animal and human studies. Clin Chim Acta 286, 11543.
  • Dawson, S. J., Wiman, B., Hamsten, A., Green, F., Humphries, S. & Henney, A. M. (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268, 1073910745.
  • Djoussé, L., Myers, R. H., Province, M. A., Hunt, S. C., Eckfeldt, J. H., Evans, G., Peacock, J. M. & Ellison, C. (2002) Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. Stroke 33, 13571361.
  • Eichner, J. E., Dunn, S., Perveen, G., Thompson, D. M., Stewartand, K. E. & Stroehla, B. C. (2002) Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155, 487495.
  • Eriksson, P., Kallin, B., van t’Hooft, F. M., Bavhenolm, P. & Hamsten, A. (1995) Allelic specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92, 18511855.
  • Festa, A., D’Agostino, R., Tracy, R. P. & Haffner, S. M. (2002) Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type II diabetes: the insulin resistance atherosclerosis study. Diabetes 51, 11311137.
  • Festa, A., Williams, K., Tracy, R. P., Wagenknecht, L. E. & Haffner, S. M. (2006) Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type II diabetes. Circulation 113, 17531759.
  • Gianola, D. & Sorensen, D. (2004) Quantitative genetic models for describing simultaneous and recursive relationships between phenotypes. Genetics 167, 14071424.
  • Grundy, S. M., Balady, G. J., Criqui, M. H., Fletcher, G., Greenland, P., Hiratzka, L. F., Houston-Miller, N., Kris-Etherton, P., Krumholz, H. M., LaRosa, J., Ockene, I. S., Pearson, T. A., Reed, J., Washington, R. & Smith, S. C. Jr. (1998) Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 97, 18761887.
  • Grundy, S. M. (1999) Primary prevention of coronary heart disease: integrating risk assessment with intervention. Circulation 100, 988998.
  • Grundy, S. M., Garber, A., Goldberg, R., Havas, S., Holman, R., Lamendola, C., Howard, W. J., Savage, P., Sowers, J., & Vega, G. L. (2002) Prevention conference VI: Diabetes and cardiovascular disease: Writing Group IV: Lifestyle and medical management of risk factors. Circulation 105(18), e153–e158.
  • Hamsten, A., de Faire, U., Walldius, G., Dahlen, G., Szamosi, A., Landou, C., Blomback, M. & Wiman, B. (1987) Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2, 39.
  • Hixson, J. E. (1991) Apolipoprotein E polymorphisms affect atherosclerosis in young males. Arterioscler Thromb Vasc Biol 11, 12371244.
  • Humphries, S. E., Lane, A., Dawson, S. & Green, F. R. (1992) The study of gene–environment interactions that influence thrombosis and fibrinolysis: genetic variation at the loci for factor VII and plasminogen activator inhibitor-1. Arch Pathol Lab Med 116, 13221329.
  • Humphries, S. E., Talmud, P. J., Hawe, E., Bolla, M., Day, I. N. & Miller, G. J. (2001) Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: A prospective study. Lancet 358, 115119.
  • Jiang, C. & Zeng, Z. B. (1995) Multiple trait analysis of genetic mapping for quantitative trait loci. Genetics 140, 11111127 (PubMed: 7672582).
  • Juhan-Vague, I., Pyke, S. D., Alessi, M. C., Jespersen, J., Haverkate, F. & Thompson, S. G. (1996) Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Study Group: European Concerted Action on Thrombosis and Disabilities. Circulation 94, 20572063.
  • Kanaya, A. M., Wassel-Fyr, C., Vittinghoff, E., Harris, T. B., Park, S. W., Goodpaster, B. H., Tylavsky, F. & Cummings, S. R. (2006) Adipocytokines and incident diabetes mellitus in older adults: The independent effect of plasminogen activator inhibitor 1. Arch Intern Med 166, 350356.
  • Keavney, B., Parish, S., Palmer, A., Clark, S., Youngman, L., Danesh, J., McKenzie, C., Delépine, M., Lathrop, M., Peto, R. & Collins, R. (2003) Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E epsilon2/epsilon3/epsilon4 genotype. Lancet 361, 396398.
  • Li, R., Tsaih, S. W., Shockley, K., Stylianou, I. M., Wergedahl, J., Paigen, B. & Churchill, G. A. (2006) Structural model analysis of multiple quantitative traits. PLoS Genet 2, 10461057.
  • Liu, S., Ma, J., Ridker, P. M., Breslow, J. L. & Stampfer, M. J. (2003) A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis 166, 323329.
  • Longford, N. T. & Muthén, B. (1992) Factor analysis for clustered observations. Psychometrika 57, 581597.
  • Mansfield, M. W., Stickland, M. H. & Grant, P. J. (1995) Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator-inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellituis. Thromb Haemost 74, 842847.
  • McCaffery, J. M., Papandonatos, G. D., Bond, D. S., Lyons, M. J. & Wing, R. R. (2009) Gene X environment interaction of vigorous exercise and body mass index among male Vietnam-era twins. Am J Clin Nutr 89, 10111018.
  • Meigs, J. B., O’donnell, C. J., Tofler, G. H., Benjamin, E. J., Fox, C. S., Lipinska, I., Nathan, D. M., Sullivan, L. M., D’Agostino, R. B. & Wilson, P. W. (2006) Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: The Framingham Offspring Study. Diabetes 55, 530537.
  • Morange, P. E., Saut, N., Alessi, M. C., Yudkin, J. S., Margaglione, M., Di Minno, G., Hamsten, A., Humphries, S. E., Tregouet, D. A. & Juhan-Vague, I. (2007) Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters The HIFMECH Study. Arterioscler Thromb Vasc Biol 27, 22502257.
  • Muthen, B. (1984) A general structural equation model with dichotomous, ordered categorical and continuous latent indicators. Psychometrika 49, 115132.
  • Muthen, B. & Satorra, A. (1996) Technical aspects of Muthen's LISCOMP approach to estimation of latent variable relations with a comprehensive measurement model. Psychometrika 60, 489503.
  • Muthen, L. K. & Muthen, B. (2004) Mplus user's guide. Los Angeles , CA : Muthen and Muthen.
  • Nadeau, J. H., Burrage, L. C., Restivo, J., Pao, Y. H., Churchill, G. & Hoit, B. D. (2003) Pleiotropy, homeostasis, and functional networks based on assays of cardiovascular traits in genetically randomized populations. Genome Res 13, 20822091.
  • Neto, E. C., Ferrara, C. T., Attie, A. D. & Yandell, B. S. (2008) Inferring causal phenotype networks from segregating populations. Genetics 179, 10891100.
  • Nock, N. L., Wang, X., Thompson, C. L., Song, Y., Baechle, D., Raska, P., Stein, C. M. & Gray-McGuire, C. (2009) Defining genetic determinants of the Metabolic Syndrome in the Framingham Heart Study using association and structural equation modeling methods. BMC Proc 3, 16.
  • Poon, W. Y. & Lee, S. Y. (1992) Maximum likelihood and generalized least squares analyses of two-level structural equation models. Stat Probab Lett 14, 2530.
  • Rabe-Hesketh, S., Skrondal, A. & Pickles, A. (2004) Generalized multilevel structural equation modeling. Psychometrika 69, 167190.
  • Rijsdijk, F. V. & Sham, P. C. (2002) Analytic approaches to twin data using structural equation models. Brief Bioinform 3, 119133.
  • Skrondal, A. & Rabe-Hesketh, S. (2004) Generalized latent variable modeling: Multilevel, longitudinal, and structural equation models. Boca Raton , FL : Chapman and Hall/CRC.
  • Smith, S. C. Jr., Jackson, R., Pearson, T. A., Fuster, V., Yusuf, S., Faergeman, O., Wood, D. A., Alderman, M., Horgan, J., Home, P., Hunn, M. & Grundy, S. M. (2004) Principles for national and regional guidelines on cardiovascular disease prevention: A scientific statement from the World Heart and Stroke Forum. Circulation 109, 31123121.
  • Song, Y., Stampfer, M. J. & Liu, S. (2004) Meta-analysis: Apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 141, 137147.
  • Stein, C. M., Song, Y., Elston, R. C., Jun, G., Tiwari, H. K. & Iyengar, S. K. (2003) Structural equation model-based genome scan for the metabolic syndrome. BMC Genet (Suppl) 4, 15.
  • Stengard, J. H., Zerba, K. E., Pekkanen, J., Ehnholm, C., Nissinen, A. & Sing, C. F. (1995) Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 91, 265269.
  • Su, S., Chen, S., Zhao, J., Huang, J., Wang, X., Chen, R. & Gu, D. (2006) Plasminogen activator inhibitor-1 gene: selection of tagging single nucleotide polymorphisms and association with coronary heart disease. Arterioscler Thromb Vasc Biol 26, 948954.
  • Talmud, P. J. (2004) How to identify gene–environment interactions in a multifactorial disease: CHD as an example. Proc Nutr Soc 63, 510.
  • Talmud, P. J., Stephens, J. W., Hawe, E., Demissie, S., Cupples, L. A., Hurel, S. J., Humphries, S. E. & Ordovas, J. M. (2005) The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: Potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet 69, 613622.
  • Talmud, P. J. (2006) Gene–environment interaction and its impact on coronary heart disease risk. Nutr Metab Cardiovasc Dis 17, 148152.
  • Utermann, G., Hees, M. & Steinmetz, A. (1977) Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 269, 604607.
  • Wilson, P. W., Schaefer, E. J., Larson, M. G. & Ordovas, J. M. (1996) Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 16, 12501255.
  • Wright, S. (1921) Correlation and causation. J Agric Res 20, 557585.
  • Yang, Q. & Khoury M. J. (1997) Evolving methods in genetic epidemiology. III: Gene–environment interaction in epidemiologic research. Epidemiol Rev 19, 3343.
  • Zhu, W. S. & Zhang, H. P. (2009) Why do we test multiple traits in genetic association studies? J Kor Stat Soc 38, 110.